Find your next paid study

Seagen, a wholly owned subsidiary of PfizerNCT05208762

Actual pay is set by the research site.

Advanced Solid TumorsOvarian CancerEndometrial Cancer+6 more

An Open-label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and/or Refractory Solid Tumors

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and …

Pheast TherapeuticsNCT06840886

Actual pay is set by the research site.

Phase 3

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The stu…

Neoplasms, Endometrial

GlaxoSmithKlineNCT07286331

~$50 – $2,250

Actual pay is set by the research site.

Endometrial NeoplasmsSoft Tissue Sarcoma (STS)Breast Neoplasms

Phase 1b/2a Clinical Study of AL58805 Combining With Other Anti-tumor Agents in Advanced, Metastatic GYN, STS or Breast Cancers

This phase 1b/2a study evaluates AL58805, an oral investigational drug that blocks PI3K and mTOR signaling, in combination with one of three anticancer treatme…

Advenchen Pharmaceuticals, LLC.NCT07811232

Actual pay is set by the research site.

Recurrent Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Primary Peritoneal Cancer+3 more

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to …

Regeneron PharmaceuticalsNCT03564340

Actual pay is set by the research site.

Cervical CarcinomaEndometrial CarcinomaOveractive Bladder+1 more

Flyte System Transvaginal Mechanotherapy for Urinary Incontinence in Endometrial and Cervical Cancer Survivors: A Pilot Study

This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among en…

Actual pay is set by the research site.

Mayo ClinicNCT07662824

The Use of a Novel Vaginal Speculum for Endometrial Biopsies

The objective of this clinical trial is to determine if a newly-designed and FDA-cleared vaginal speculum (the Bouquet Speculum) will provide better visualizat…

Endometrial Cancer

Rocky Vista University, LLCNCT07217353

Actual pay is set by the research site.

Gynecologic CancerEndometrial CancerCervical Cancer+2 more

Mindfulness Practice in Endometrial and Cervical Cancers With Smartphone Applications (MECCA)

Patients with endometrial cancer who will be undergoing surgery or patients with cervical cancer who will be treated with chemoradiation will be randomized to …

St. Louis UniversityNCT04512144

Actual pay is set by the research site.

Ovarian CancerEndometrial CancerPlatinum-resistant Ovarian Cancer (PROC)+2 more

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.

This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian o…

ArriVent BioPharma, Inc.NCT07755436

Actual pay is set by the research site.

Phase 3

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's…

Endometrial CancerMalignant Solid Tumour

~$50 – $2,250

Actual pay is set by the research site.

AstraZenecaNCT07044336

Breast CancerCervical CancerBladder Cancer+4 more

An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episo…

Medical College of WisconsinNCT07227077

Actual pay is set by the research site.

Ovarian CancerLung AdenocarcinomaEndometrial Cancer+1 more

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is saf…